fda glp-1 warning letters news September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns – Partnership for Safe Medicines Today, the FDA issued 18

If GI symptoms are severe or persistent beyond three weeks at any given dose, consult your healthcare provider rather than pushing to the next escalation level

Most GLP-1 meds are once-weekly, and the needle is very small

Reference: RETADPEN10 Retatrutide Disposable Pen Retatrutide is a powerful triple agonist peptide that targets GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptorsmaking it the most comprehensive metabolic peptide in its class

This increase has been associated with more frequent reports of allergic reactions

So its actually twofold, the duties themselves plus the capital to put your infrastructure in place, which is obviously then you lose your ultra-low cost advantage and you You have to align more with the Amazon, or you abandon the market, which, and Im no expert there, but I would tend to think that this is not something they want to do